The Clinical Observation Of The Role That Dexrazoxane Plays On Prevention Of Cardiac Toxicity Caused By Epirubicin

Objective:To observe the role that dexrazoxane plays on prevention of cardiactoxicity caused by epirubicin.Method:61cases of patients with breast cancer and lymphoma who weretreated in the second clinical hospital of jilin university in January2012-August2013were selected, and were randomly divided into thechemotherapy combined with dexrazoxane group (group A) andchemotherapy alone group(group B).All the patients got six cycles ofchemotherapy according to their own disease.All the patients with breastcancer were treated with TE regimen:epirubicin75mg/m2on day1,ivgtt;docetaxel75mg/m2on day2,ivgtt.All the patients with lymphomawere treated with CHOP regimen:cyclophosphamide750mg/m2on day1,iv;vincristine1.4mg/m2on day1,iv;epirubicin80mg/m2on day1,ivgtt;prednisone100mg/m2on day1-5,po.Chemotherapy cycles wereonce every3weeks.The usage of the dexrazoxane in group A:accordingto the dexrazoxane and epirubicin10:1proportion rapid intravenous drip,30min before giving epirubicin.Observed the changes ofelectrocardiogram(ECG), creatine kinase (CK-MB), cardiac troponinmeasurement (cTn), echocardiographic measurements of left ventricularejection fraction (LVEF).Results:Two groups of patients with abnormal ECG rate increased with thenumber of cycles of chemotherapy.After six cycles ofchemotherapy,abnormal ECG rate was29%in group A and60%in groupB.A group of abnormal ecg rate lower than that of group B,and the difference was statistically significant after4cycles of chemotherapy（P<0.05）.The creatine kinase isoenzyme (CK-MB) changes were notobvious in both two groups,and the difference was not statisticallysignificant(P>0.05).Two groups of patients cardiac troponin (cTn) wereincreased with the number of cycles of chemotherapy increased.Group Amyocardial calcium protein (cTn) lower than group B,and the differencewas statistically significant after4cycles of chemotherapy（P<0.01）.Twogroups of patients left ventricular ejection fraction (LVEF) decreased withthe number of cycles of chemotherapy increased.Group A left ventricularejection fraction (LVEF) higher than group B,and the difference wasstatistically significant after4cycles of chemotherapy（P<0.01）.Conclusion:Dexrazoxane has some prevention and cure function for cardiactoxicity caused by epirubicin.